Advertisement
Singapore markets closed
  • Straits Times Index

    3,322.62
    +14.72 (+0.45%)
     
  • S&P 500

    5,319.04
    +12.03 (+0.23%)
     
  • Dow

    39,404.42
    -266.62 (-0.67%)
     
  • Nasdaq

    16,934.48
    +132.94 (+0.79%)
     
  • Bitcoin USD

    67,989.12
    -2,461.44 (-3.49%)
     
  • CMC Crypto 200

    1,476.60
    -26.06 (-1.73%)
     
  • FTSE 100

    8,342.62
    -27.71 (-0.33%)
     
  • Gold

    2,345.20
    -47.70 (-1.99%)
     
  • Crude Oil

    77.11
    -0.46 (-0.59%)
     
  • 10-Yr Bond

    4.4890
    +0.0550 (+1.24%)
     
  • Nikkei

    39,103.22
    +486.12 (+1.26%)
     
  • Hang Seng

    18,868.71
    -326.89 (-1.70%)
     
  • FTSE Bursa Malaysia

    1,629.18
    +7.09 (+0.44%)
     
  • Jakarta Composite Index

    7,222.38
    +36.34 (+0.51%)
     
  • PSE Index

    6,659.99
    +52.77 (+0.80%)
     

Knight Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Knight Therapeutics (TSE:GUD) First Quarter 2024 Results

Key Financial Results

  • Revenue: CA$86.6m (up 4.9% from 1Q 2023).

  • Net loss: CA$4.55m (loss widened by 16% from 1Q 2023).

  • CA$0.045 loss per share (further deteriorated from CA$0.035 loss in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Knight Therapeutics Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 8.9%. Earnings per share (EPS) missed analyst estimates.

Looking ahead, revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in Canada.

ADVERTISEMENT

Performance of the Canadian Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. See our latest analysis on Knight Therapeutics' balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.